Author Index to Volumes 30, 31, and 32

Acton RT, 30:41, 208
Ahmed-Ansari A, 31:123
Akkoc N, 30:91
Al-Daccak R, 31:277
Albert ED, 31:7, 186
Allsopp CEM, 30:105
Alpérovitch A, 31:94
Amos DB, 30:236
Andersen V, 30:27
Anderson GD, 31:47
Ando A, 31:246; 32:221
Andreas A, 31:7
Angelini G, 32:157
Arendse B, 31:14
Arnaiz-Villena A, 31:134; 32:170
Auerbach AD, 30:45
Auffray C, 31:40

Baan CC, 30:50
Babcock D, 32:194
Bach FH, 30:262
Bach J-F, 32:1
Bakke AC, 32:194
Bakker K, 32:31
Bal V, 32:110
Balk AHMM, 30:50
Barber LD, 32:110
Bardie R, 31:251
Bartholomew M, 31:236
Batchelor JR, 30:174; 32:119
Baxter-Lowe LA, 31:114
Begovich AB, 31:20
Belich MP, 32:254
Bell JI, 32:56
Berr C, 31:94
Bettinotti MdlP, 31:7
Betuel H, 30:85, 183; 32:95
Bias W, 30:129
Bidwell EA, 30:136
Bidwell JL, 30:136
Bines SD, 32:134
Bodmer JG, 31:186, 207
Bodmer W, 30:259
Bodmer WF, 31:186
Bolsover WJ, 31:100
Bontrop R, 32:31
Bontrop RE, 30:11; 31:34; 32:65
Bos E, 30:50
Bowen MB, 31:67
Braun LA, 31:241
Braun MP, 32:194
Brewster D, 30:105
Brick-Ghannam C, 30:202
Brookes P, 32:119
Broxmeyer HE, 30:45
Bühring HJ, 31:165
Bunce M, 30:105
Burlingham WJ, 32:125
Butch AW, 31:67
Bux J, 30:18

Cambon-Thomsen A, 31:94
Cameron PU, 31:34
Campbell RD, 32:102
Caraballo L, 32:157
Carcassi C, 31:159
Charron D, 30:202; 31:251, 259, 261
Chertkoff LP, 31:153
Chong ASF, 32:134
Christiansen FT, 31:34
Ciclitira PJ, 31:100
Claas FHJ, 30:50, 156, 234
Clanet M, 31:94
Clot J, 32:162
Colombani J, 31:277
Concannon P, 32:277
Contu L, 31:159
Coon JS, 32:134
Corell A, 31:134; 32:170
Coto E, 31:77
Cowan EP, 32:203
Cowell V, 32:46
Cullen C, 31:145
Cullen CG, 30:1

Dalhoff K, 30:27
Daryl O, 30:222
Davey MP, 32:194
Davey N, 32:119
David CS, 31:47
Davidson ML, 30:168
Dawkins RL, 31:34
Dawson JR, 30:155
de Koster HS, 31:241
de Waal LP, 32:65
Dec WG, 32:241
Demopulos JT, 30:41
Deschamps Y, 31:271
DeVito LD, 32:125
Diedrichs-Möhring M, 31:286
Doménech N, 30:140
Domínguez O, 31:77
Drabbels J, 32:246
Drabbels JJM, 31:241
Drover S, 31:293
du Toit ED, 31:14
Duffy B, 31:1
Dugoujon J-M, 31:94
Dupont B, 31:186

Eidne K, 31:57
Eiermann TH, 30:22
El-Barrawy M, 30:222
Eliaou J-F, 32:162
Epplen JT, 31:286
Erlich HA, 30:45, 110, 190; 31:20, 186, 241
Essed CE, 30:50

Fainboim L, 31:153
Falco M, 31:86
Fallon JT, 32:241
Farre A, 30:85, 183
Fathman CG, 31:20
Fernandez-Viña M, 30:60; 31:139
Ferrara GB, 31:86; 32:157
Fischer A, 31:40
Fisher H, 30:222
Flanagan BF, 30:162
Francis DA, 32:119
Freidel AC, 30:85, 183
Freidel C, 32:95
Frelinger JA, 32:183
Friis J, 30:27
Frisman DM, 32:241
Fronek Z, 30:77
Fugger L, 30:27

Gao X, 30:147; 32:269
Garchon H-J, 32:1
Garcia E, 30:129
Gaudernack G, 30:226
Gebel HM, 32:134
Gebuhrer L, 30:85, 183; 32:95
Geraets DP, 32:141
Gijbels Y, 30:156
Giphart M, 31:34

Giphart MJ, 31:241; 32:141, 246
Gjertsen HA, 30:226
Gorski J, 31:114
Granados J, 30:129
Greenwood BM, 30:105
Griffith RL, 30:45, 190
Grosmaire LS, 32:85
Grossi CE, 30:208
Gu L-B, 31:123
Gu X-F, 31:251
Gutiérrez V, 31:77
Gutknecht J, 31:28
Gyllensten UB, 30:110

Hadley G, 31:1
Haga JA, 32:79
Hakala M, 30:7
Halberg P, 30:27
Hall MA, 31:100; 32:56
Hancock RJT, 32:110
Hannestad K, 31:271
Hansen JA, 30:32; 32:85, 229
Hansen T, 31:271
Hashimoto T, 31:246
Hawkins S, 30:1
Hayden JB, 32:194
Haynes BF, 31:148
Heilmann C, 30:27
Herrera M, 31:153
Herskowitz A, 31:123
Hill AVS, 30:105
Hinzpeter M, 31:7
Hiraiwa M, 32:41
Hodge TW, 30:41, 99
Hood L, 32:277
Hood LE, 31:77
Houck J, 31:236
Hughes A, 30:105
Hurley CK, 31:109; 32:46, 150
Hurwitz AA, 32:241

Ilonen J, 30:7
Inoko H, 31:47, 246; 32:221, 261

Jaeger EEM, 32:56
Jakobsen BK, 30:27
Jaraquemada D, 30:215; 31:229
Jeannet M, 32:95
Jimenez S, 32:157
Johnson AH, 31:109; 32:46, 32:150
Johnson JP, 31:81
Johnson PM, 30:162
Joliviere A, 31:261
Jonker M, 30:11
Jonker M, 31:34; 32:31
Ju L-Y, 31:251
Julkunen I, 32:72
Jutte NHPM, 30:50

Kang AH, 31:148
Kano K, 32:41
Kanter K, 31:123
Kao KJ, 32:79
Karaki S, 32:41
Karp DR, 31:229
Karr RW, 32:150
Karup Pedersen F, 30:27
Kasahara M, 31:28; 32:211
Kato S, 32:261
Kawai J, 32:221
Keraan M, 31:57
Kevany M, 30:174
Klein D, 32:211
Klein J, 30:247; 31:28; 32:211
Klitz W, 31:20
Kloszewski F, 31:236
Krishnamoorthy R, 31:251
Kun L, 31:86
Kurnick JT, 32:241
Kwiatkowski D, 30:105
Kwok WW, 31:81

Labonne M-P, 30:85, 183
Lamb JR, 32:110
Lambert J, 30:85, 183
Lanchbury JSS, 32:56
Lando D, 31:261
Lane VG, 30:208
Lara ML, 30:129
Lardy NM, 32:65
Lattouf O, 31:123
Lawlor DA, 30:119
Layrisse Z, 30:129
Lechler RI, 30:174; 32:110, 119
Ledbetter JA, 32:85
Lee KW, 31:109; 32:150
Lethielleux P, 31:277
Levine A, 31:67
Lichtiger B, 30:222
Lipsky PE, 31:148
Lledó G, 31:134
López de Castro JA, 30:140
López-Larrea C, 31:77
Loiseau P, 31:277
Lombardi G, 30:174
Long EO, 31:229
Lundin KEA, 30:226

Mäkelä O, 32:72
Mach B, 30:278; 31:186; 32:95
Mackworth-Young CG, 30:174
Malnati M, 31:229
Margulies DH, 32:125
Markham PN, 32:134
Marrugo J, 32:157
Marsh SGE, 31:186, 207
Marshall WH, 31:293
Martell RW, 31:14
Martínez-Naves E, 31:77
Martin J, 31:145
Martin PJ, 30:32; 32:85, 229
Martin-Villa JM, 31:134; 32:170
Martinez-Laso J, 31:134; 32:170
Masewicz S, 31:109; 32:229
Masewicz SA, 30:32
Mason B, 32:125
Matsumoto K, 32:41
Mayr WR, 31:186
Mazerolles F, 31:40
Mazzoleni O, 31:86
McDevitt HO, 30:77
McDonald WI, 32:119
McDougal JS, 30:99
McFarland HF, 32:203
McFarlin DE, 32:203
McGregor AM, 30:136
McMichael AJ, 30:105
Mehra NK, 32:246
Meyer MM, 32:194
Mickelson E, 31:109
Mickelson EM, 30:32; 32:229
Middleton D, 30:1; 31:145
Millar RP, 31:57
Miller S, 30:147
Mohanakumar T, 31:1
Mohanam S, 31:1
Molkentin J, 31:114
Mooney N, 30:202
Moraes JR, 30:147
Moraes ME, 30:60; 31:139
Morales P, 31:134; 32:170
Morling N, 30:27
Mühlegger K, 31:7
Müller CR, 30:22
Mueller-Eckhardt C, 30:18
Mueller-Eckhardt G, 30:18
Munkirs DD, 32:194

Nagao T, 32:41
Nahm MH, 31:67
Narimatsu H, 31:246
Nepom GT, 30:32; 32:229
Nevinny-Stickel C, 31:7
Niizeki H, 31:246
Nishikawa T, 31:246
Nomura N, 32:261
Nordwig H, 31:81
Noreen HJ, 30:168
Norris NA, 32:85

O'Hehir RE, 32:110
O'hUigin C, 32:211
Odum N, 32:85
Ober C, 32:235
Okamoto N, 32:221

Orr HT, 31:180
Ota M, 32:261
Otting N, 30:11
Oudshoorn M, 31:14
Ouwehand AJ, 30:50
Oxholm P, 30:27

Pachman L, 32:235
Panayi GS, 32:56
Parham P, 30:119; 31:186, 195
Parlevliet J, 32:141
Parvin CA, 31:67
Pawelec G, 31:165
Pazmany L, 30:105
Pérez-Aciego P, 32:170
Petersdorf E, 32:229
Petzl-Erler ML, 32:254
Phelan D, 31:1
Pierce ML, 32:203
Pinet V, 32:162
Pisetsky DS, 31:148
Pistillo MP, 31:86
Pollack MS, 30:45
Pook MA, 32:102, 176
Postlethwaite AE, 31:148
Prasthofer EF, 30:208
Puel J, 31:94
Pyhälä R, 32:72

Queiroz-Telles F, 32:254

Ratanachaiyavong S, 30:136
Ratanjee B, 31:57
Rautonen N, 32:72
Reed AM, 32:235
Reijonen H, 30:7
Ress SR, 31:57
Rich SS, 30:168
Riley WJ, 32:79
Risk JM, 30:162
Ronningen KS, 30:69, 226
Romano PJ, 31:236
Rosen-Bronson S, 30:215; 31:229
Rousseau J, 31:57
Ruberti G, 31:20
Rubinstein P, 30:270
Ruidavets J-B, 31:94
Ryder LP, 30:27

Sansom DM, 32:56
Santamaria P, 30:168
Santos-Aguado J, 30:140
Sarvas H, 32:72
Sasazuki T, 31:186
Sasso DR, 30:99
Satz ML, 31:153
Savage DA, 30:1; 31:145
Savarirayan S, 31:47
Scharf SJ, 30:190
Schendel DJ, 31:286
Schieven GL, 32:85
Schmidt CM, 31:180
Schmitz G, 31:7
Schneck J, 32:125
Schönbach C, 31:28; 32:211
Schreuder GMTh, 31:186; 32:141
Schroeijers WEM, 31:241
Scornik JC, 30:91
Scorza JV, 30:129
Segall M, 30:168
Sekaly RP, 31:229
Sell KW, 31:123
Serjeantson SW, 32:269
Setién F, 31:77
Sharrock C, 30:174
Sidhu S, 30:174
Singh SPN, 32:246
Slierendregt B, 32:31
Slierendregt BL, 30:11
Smith A, 32:229
Smith PJ, 31:236
Sollinger HW, 32:125
Sonoda A, 31:246
Spies T, 30:27
Spurkland A, 30:69
Stastny P, 30:60, 147; 31:139
Stedeford J, 32:56
Steere AC, 31:20
Stoikow Z, 30:129
Strachan T, 32:102, 176
Strominger JL, 30:27; 31:186
Stryker J, 31:236
Summers CW, 32:102, 176
Svejgaard A, 30:27; 31:186

t'Hart B, 32:31
Tadakuma T, 31:246
Takata H, 31:246
Takiguchi M, 32:41
Taneja V, 32:246
Tang T, 32:150
Tang TF, 32:46
Tassabehji M, 32:102
Taylor CJ, 30:105
Taylor M, 32:102
Tazzari PL, 31:86
Temime N, 31:261
Terasaki PI, 31:186
Termijtelen A, 31:241
Teyton L, 31:261
Theophille D, 31:277
Thompson AJ, 32:119
Thorsby E, 30:69, 226
Tiercy J-M, 30:278; 32:95
Tiilikainen A, 30:7
Tilden AB, 30:208
Timmerman LA, 30:77
Toubert A, 31:271
Townend D, 31:34
Trucco G, 31:159
Trucco M, 31:159
Tsuji K, 31:246; 32:221, 261
Tussey LG, 32:183

Urban ND, 31:170
Urra JM, 31:77

Vaessen LMB, 30:50
van Bree S, 30:156
van den Berg-Loonen EM, 32:65
van den Berg-Loonen PM, 32:141
van der Horst AR, 32:65
van Rood JJ, 30:156; 31:241; 32:141
van Veen A, 30:156
Vandvik B, 30:69
Varela P, 32:170
Vartdal F, 30:69
Vaughan RW, 31:100
Verduijn W, 32:246
Verduyn W, 31:241; 32:141
Vesell ES, 31:236
Vicario JL, 31:134; 32:170
Vincek V, 32:211

Wang FQ, 31:277
Wang Y, 32:134
Wang Y-C, 31:123
Weimar W, 30:50
Welsh KI, 31:100
Weyl D, 31:271
Woodcock V, 32:102, 32:176
Wooten V, 30:41
Wordsworth P, 32:56
Wright JA, 32:277

Yamamoto J, 32:41
Yendle J, 32:110
Yoshiwara T, 32:221
Yu W-Y, 32:150

Zaafran A, 30:45
Zarcone D, 30:208
Zemmour J, 31:195
Zhang L, 30:156
Zhang WJ, 31:34
Zhou P, 31:47
Zier KS, 31:170

Subject Index to Volumes 30, 31, and 32

Abortion, recurrent spontaneous and CD46 gene polymorphism, 30:162
Abstracts, ASHI 17th Annual Meeting, 1991, 32:Supplement 1
Activated T cells, *See* T cells, activated
Age, Gm allotype influence on IgG3 production and, 32:72
Alloantiserum MSD-51, epitope mapping of HLA-DRw53, 32:65
American blacks,
  DR-2 positive, a novel DRB1 allele, 30:41
  HLA-DRw8 microvariation in, 31:109
American cutaneous leishmaniasis, *See* Leishmaniasis, human cutaneous
American Society for Histocompatibility and Immunogenetics (ASHI), 17th Annual Meeting, 1991, abstracts, 32:Supplement 1
Anti-CD6 monoclonal antibodies, preferential stimulation of TCR γ/δ^+ T-cell clones, 31:165
Anti-HLA alloantibodies, intramolecular specificity, 30:91
Anti-HLA-DR monoclonal antibody, 30:174
Anti-idiotypic antibodies, to HLA class I alloantibodies, tolerance, 31:1
Arthritis, Lyme, susceptibility and HLA class II genes DRB1, DQA1, DQB1, DPB1, 31:20
Arthritis, rheumatoid,
  autocrine stimulation of IL-1 by adherent
  Finnish patients, HLA-B27 bearing HLA haplotypes in, 30:7
  meeting report re: Specialized Centers of Research in, 31:148
  synovial lining cells, 31:261
Asian Indian population, HLA-DR2-associated polymorphisms, 32:246
Asthma, allergic, frequency of HLA-DPB1*0401 in, 32:157
Australian aborigines, HLA-DR4-related HLA-DR,DQ haplotypes, 32:269
Autoimmune diseases, contribution of non-MHC genes, 32:1
Autoimmunity,
  human immunology, an editorial, 31:259
  IDDM and a new HLA-DR2 extended haplotype, 31:159
  neutrophil-specific NA1 antigen, association with HLA-DR2, 30:18
  Non-human primates, role of MHC and T cells, 32:31
  RFLP analysis of HLA-B associated transcripts genes, 30:27

B-cell response, in highly sensitized patients to HLA class I alloantigens, 30:156
B lymphocytes, signal transduction in, 30:202
Bone marrow transplantation, HLA-DPB1 disparity and G*v*H disease, 32:261
Cancer, T-cell immune response to, 30:259
Cardiac myocytes, human, MHC class I/II expression by, influence of cytokines and immunosuppressive drugs, 31:123
Cardiac transplants,
  alloreactive lymphoid infiltrates, 30:50
  cytotoxic activity of graft infiltrating lymphocytes and graft rejection, 32:241
Caucasoid population,
  HLA-DPB1 and HLA-DPA1 gene polymorphism and associations, 31:277
  North American, multiple sclerosis and HLA-DR and -DQ, 32:203
C4 allotyping, chimpanzee, ancestral haplotypes, 31:34
CD4, down regulation of T-cell adhesion, an hypothesis, 31:40
CD4 and CD45 crosslinking, inhibition of HLA-Dr induced signal transduction, 32:85
CD4 antigen epitope deficiency, a CD4 gene single nucleotide base change and, 30:99
CD46 gene polymorphism, 30:162
CD6, monoclonal antibodies to preferentially stimulate T-cell clones with γ/δ receptors, 31:165
cDNA expression vectors, HLA-DR, 31:229
Celiac disease, HLA-DP associations and an extended HLA-DR3 haplotype, 31:100
Chimpanzee C4 allotyping, ancestral haplotypes, 31:34
Chinese, HLA-DR4-related HLA-DR,DQ haplotypes, 32:269
CpG island-associated gene, identification and orientation adjacent to HLA-DNA, 32:221
Cytokines, influence on expression of MHC class I/II by cardiac myocytes, 31:123

Dermatomyositis, juvenile, increased risk associated with HLA-DQA1*0501, 32:235
Detergents, effects on HLA class I peptide binding, 32:183
Diabetes mellitus, insulin-dependent,
  association with HLA-DRB1*0405-(Dw15)-DQw8 haplotype in Spaniards, 32:170
  DNA typing of HLA-DR4 subsets in, 31:251
  germline repertoire of TCR β-chain genes, 31:77
  HLA and, 30:270
  HLA-DQ and susceptibility, 31:134
  new HLA-DR2 extended haplotype and susceptibility, 31:159
Digoxigenin-11-2'-3'-dideoxy-uridinetriphosphate-labeled oligonucleotide probes, 31:7
DNA amplification, DQ typing and prenatal HLA typing for identification of potential donors for umbilical cord blood transplantation, 30:45

DNA typing,
HLA class II, from the bench to the bedside, 30:278
HLA class II, nonradioactive, 31:7
HLA-DP, allele-specific or group-specific amplification, 30:60
HLA-DQB1 alleles, detection by nonradioactive oligotyping, 31:114
HLA-DR1 and DR'Br', 30:147
HLA-DR2 alleles, with allele-specific or group-specific amplification, 31:139
HLA-DRB1 sequence polymorphism, 30:190
identification of stimulatory antigens in MLC, 31:241
nonradioactive method, HLA-DR4 subsets in IDDM, 31:159

Editorials,
autoimmunity in human immunology, 31:259
Jon van Rood, retirement, 30:234
manuscript revision, 30:155
Epitope analysis,
anti-HLA class I alloantibodies and, 30:91
HLA-A2 and HLA-B7, site-specific mutagenesis at residues 62-80, 30:140
HLA-B27, natural and mutated variants, 31:271
HLA-DRw53 and the alloantiserum MSD-51, 32:65
HLA-Dw14 with T-cell clones, 32:229
monoclonal antibody defined DQw1 determinants, 31:81
monoclonal antibody with broad anti-HLA-DR activity, 30:174
T-cell recognition of HLA-Bw4/Bw6, 32:41
Evolution,
allelic diversity of the primate MHC class II loci, 30:110
class I MHC genes in humans and apes, 30:119
Experimental autoimmune encephalomyelitis (EAE), RFLP analysis of rhesus monkeys, 30:11

Fanconi anemia, umbilical cord blood transplantation, DNA amplification for DQ typing, 30:45
Felty's syndrome, HLA-DQw7 association and, 32:56
Finns, rheumatoid arthritis patients, HLA-B27 bearing HLA haplotypes in, 30:7

Gene conversion, HLA-DR5x6, 30:168
Germinal center T cells, a distinct subset, 31:67
Gm allotypes, influence on the production of IgG3, 32:72
Gogo-DRB pseudogene, relation to HLA-DRBVIII, 32:211
Gorilla MHC DRB, *See* Gogo-DRB pseudogene
Graft infiltrating lymphocytes,
cytotoxic activity and graft rejection in cardiac transplant patients, 32:241
heart transplants, 30:50
Graft-Versus-Host (G*v*H) disease, HLA-DPB1 disparity in bone marrow transplantation, 32:261

Herbimycin, inhibition of HLA-DR mediated signal transduction in activated T cells, 32:85
Highly sensitized patients, humoral and cytotoxic T-cell responses to HLA class I alloantigens in, 30:156
HLA, fundamental antigens, 30:236
HLA and IDDM, the disease gene, facts and speculation, 30:270
HLA and lung carcinoma, 31:236
HLA around the world, a pictorial history, 30:285
HLA class I alloantibodies, anti-idiotypic antibodies to and tolerance, 31:1
HLA class I alloantigens, humoral and cytotoxic T-cell responses in highly sensitized patients, 30:156
HLA class I genes, transcriptional patterns of expression, 32:176
HLA class I nucleotide sequences, 1991, 31:195
HLA class I soluble alloantigens in plasma, effect of HLA phenotype and gender on expression, 32:79
HLA class I variants, HLA-B35 from a Caucasian of Hispanic origin, 31:153
HLA class I/II expression by human cardiac myocytes, influence of cytokines and immunosuppressive drugs, 31:123
HLA class II antigens, association with pemphigus vulgaris in Japanese patients, 31:246
HLA class II DNA typing, nonradioactive, 31:7
HLA class II expression on activated T cells, TNF-α treatment, 31:286
HLA class II genes, susceptibility to Lyme arthritis and, 31:20
HLA class II genotyping, from the bench to the bedside, 30:278
HLA class II induction, K562 variant cell line and IFN-γ, inhibition by serum lipid, 31:57
HLA class II markers, multiple sclerosis, 31:94
HLA class II molecules, negative signal transmission through on activated T cells, 31:170
HLA class II molecules, signal transduction, 30:202
HLA class II nucleotide sequences, 1991, 31:207
HLA class II typing, serologic analysis of PHA and IL-2 stimulated peripheral blood mononuclear cells, 30:222
HLA gene transfection, genomic DNA, 31:293
HLA haplotypes and human cutaneous leishmaniasis, 30:129
HLA nomenclature, WHO committee report, 1990, 31:186
HLA nonclassical class I genes, 31:180
HLA phenotype, effect on expression of HLA class I in plasma, 32:79
HLA-A2, secreted molecule, binding to solid phase peptides, 32:183
HLA-A2 and HLA-B7, antigenicity, 30:140
HLA-A2/Q10^b secreted fusion protein, immunochemical analysis, 32:125
HLA-B associated transcripts genes (HLA-BATs), RFLP analysis in five autoimmune diseases, 30:27
HLA-B27 bearing HLA haplotypes, Finnish rheumatoid arthritis patients, 30:7
HLA-B27 epitope mapping, human monoclonal antibodies reacting with natural and mutated variants, 31:271
HLA-B35, complete nucleotide sequence of a genomic clone isolated from a Caucasian of Hispanic origin, 31:153
HLA-B35 gene conversion, origin of HLA-Bw53, 30:105
HLA-Bw4/Bw6 public epitopes, T-cell recognition, 32:41
HLA-Bw53, sequence analysis, gene conversion of HLA-B35

and origin, 30:105
HLA-DNA gene, orientation in the MHC class II region, 32:221
HLA-DP and celiac disease, 31:100
HLA-DP DNA typing, allele-specific or group-specific amplification for, 30:60
HLA-DPB1 and HLA-DPA1 gene polymorphism and associations, in Caucasoid population, 31:277
HLA-DPB1 disparity, GvH disease in bone marrow transplantation, 32:261
HLA-DPB1 typing, sequence-specific oligonucleotide probes, 30:22
HLA-DPB1*0401 and allergic asthma, a mulatto population, 32:157
HLA-DQ αβ heterodimer, T-cell recognition, cis encoded by the DR4,DQw4 haplotype and in trans by DR4,DQw8/DRw8,DQw4 heterozygous cells, 30:226
HLA-DQ and susceptibility to IDDM, 31:134
HLA-DQ β chain, presentation of *Mls* locus gene products and deletion of Vβ6⁺, Vβ8.1⁺ T cells, 31:47
HLA-DQ1 epitopes, monoclonal antibody defined, 31:81
HLA-DQA1 and HLA-DQB1 genes, susceptibility to multiple sclerosis, 30:69
HLA-DQA1*0501 and juvenile dermatomyositis, 32:235
HLA-DQA2 alleles, linkage disequilibrium with the HLA-DR/DQ complex, 30:136
HLA-DQB1 and IDDM, 30:270
HLA-DQB1 oligotyping, nonradioactive probes, 31:114
HLA-DQB1 rare allele, sequence of in patients with systemic lupus erythematosus, 30:77
HLA-DQ/DRw52, unique associations with HLA-DRw11 haplotypes, 32:150
HLA-DQw3 mucocutaneous leishmaniasis, 32:254
HLA-DQw3 variants, identification with alloreactive T-cell clones, 30:32
HLA-DQw7, association with HLA-DRw8 microvariation in American blacks, 31:109
HLA-DQw7 and Felty's syndrome, 32:56
HLA-DQw7,DRw11 cellular subtypes, 30:183
HLA-DR and HLA-DQ, susceptibility to multiple sclerosis, 32:119
HLA-DR and HLA-DQ allelic sequences, multiple sclerosis in North American caucasoids, 32:203
HLA-DR and HLA-DQ DNA genotyping, Northern Irish multiple sclerosis patients, 30:1
HLA-DR cDNA expression vectors, transient expression in transfected fibroblasts and lymphoid cells, 31:229
HLA-DR/DQ linkage disequilibrium, the HLA-DQA2 alleles, 30:136
HLA-DR1 and HLA-DR'Br' DNA typing, use of allele specific or group specific amplification, 30:147
HLA-DR2, association with autoimmunization to neutrophil-specific NA1 antigen, 30:18
HLA-DR2, increasing complexity and new haplotypes, 32:141
HLA-DR2 and mucocutaneous leishmaniasis, 32:254
HLA-DR2 extended haplotype, new, involvement in IDDM susceptibility, 31:159
HLA-DR2 typing, allele-specific or group-specific amplification and DNA typing, 31:139
HLA-DR2a and HLA-DR2b, T-cell recognition of and relative immunogenicity of, 30:215
HLA-DR2-associated polymorphisms, analysis in an Asian Indian population, 32:246
HLA-DR3 extended haplotype and celiac disease, 31:100
HLA-DR3 microvariants, HLA-DRw17 and HLA-DRw18, T-cell recognition, 32:46
HLA-DR4 Dw10, contribution of peptide binding and TCR contracting residues to serologic and T-cell recognition, 32:110
HLA-DR4 subsets, nonradioactive method of DNA typing in IDDM, 31:251
HLA-DR4 subtype, HLA-Dw4, and Felty's syndrome, 32:56
HLA-DR4 subtypes, frequencies in Spanish IDDM patients, 32:170
HLA-DR4-related HLA-DR,DQ haplotypes, diversity in Australia, Oceania, and China, 32:269
HLA-DR4,DQw4 haplotype, T-cell recognition of a cis encoded αβ heterodimer, 30:226
HLA-DR4,DQw4/HLA-DRw8,DQw4 heterozygous cells, T-cell recognition of a trans encoded αβ heterodimer, 30:226
HLA-DR5x6, serology, RFLP and sequence analysis of a unique class II antigen, 30:168
HLA-DRA polymorphism, regulatory region, 32:162
HLA-DRB1 novel allele, DR-2 positive American blacks, 30:41
HLA-DRB1 polymorphism,
  DNA typing, 30:190
  new Taq 1 RFLPs, 31:145
HLA-DRB1*0405-(Dw15)-DQw8 haplotype, IDDM in Spaniards, 32:170
HLA-DRBVIII and Gogo-DRB8, 32:211
HLA-DR,DQ haplotypes, unusual, found in South African families, 31:14
HLA-DRw8 microvariation, new DRB1 allele associated with DQw7 in American blacks, 31:109
HLA-DRw8+w12, human monoclonal antibody to, 31:86
HLA-DRw11, human monoclonal antibody to, 31:86
HLA-DRw11 haplotypes, continuum of DRB1 diversity, unique DQ/DRw52 associations, 32:150
HLA-DRw11 microvariation, 32:15
HLA-DRw11,DQw7 cellular subtypes, 30:183
HLA-DRw13 polymorphism, 32:95
HLA-DRw13,DQw7 haplotypes,
  diversity revealed by serology and RFLP, 30:85
  new, sequence analysis, 32:95
HLA-DRw17 and HLA-DRw18, T-cell recognition, 32:46
HLA-DRw53, epitope mapping with alloantiserum MSD-51, 32:65
HLA-Dw4 subtype of HLA-DR4, Felty's syndrome association with HLA-DQw7, 32:56
HLA-Dw14 epitopes, 32:229
HLA-F, a physical linkage map of MHC nonclassical class I genes, 31:180
HLA-G, a physical linkage map of MHC nonclassical class I genes, 31:180

HLA-G, characterization of a new allele, 32:102
HLA-7.5, a physical linkage map of MHC nonclassical class I genes, 31:180
Hybridomas, human, monoclonal antibodies to HLA-DRw11 and HLA-DRw8+w12 specificities, 31:86

IgG3, Gm allotypes influence on production, 32:72
Immunogenicity of HLA-DR alloantigens, T-cell recognition of HLA-DR2a and HLA-DR2b, 30:215
Immunosuppressive drugs, influence on expression of MHC class I/II by cardiac myocytes, 31:123
Insulin-dependent diabetes mellitus (IDDM), *See* Diabetes mellitus, insulin-dependent
Interferon-γ (IFN-γ),
  down regulation of IL-1 synthesis by adherent synovial lining cells, 31:261
  inhibition of HLA class induction by serum lipid, 31:57
Interleukin-1 (IL-1), autocrine stimulation in adherent synovial lining cells, 31:261
Interleukin-2 (IL-2) and phytohemagglutinin, peripheral blood mononuclear cell response and serologic typing for MHC class II antigens, 30:222

Jon J. van Rood Symposium, 30:233
Juvenile dermatomyositis, *See* Dermatomyositis, juvenile

Leishmaniasis, human cutaneous, immunogenetics of HLA haplotypes, 30:129
Leishmaniasis, mucocutaneous, association with HLA, 32:254
Lung carcinoma, HLA antigens and resistance to, 31:236
Lyme arthritis, *See* Arthritis, Lyme

Meeting report, Specialized Centers of Research in Rheumatoid Arthritis (SCOR), 31:148
Melanesians, HLA-DR4-related HLA-DR,DQ haplotypes, 32:269
MHC, history, 30:236
MHC ancestral haplotypes in the chimpanzee, C4 allotyping, 31:34
MHC and autoimmunity in non-human primates, 32:31
MHC and parasites, coevolution, an essay, 30:247
MHC class I genes,
  evolution of in humans and apes, 30:119
  transcriptional patterns of expression, 32:176
MHC class I/II expression by human cardiac myocytes, influence of cytokines and immunosuppressive drugs, 31:123
MHC class II DR subregion, Rhesus monkey, RFLP analysis of, 30:11
MHC class II loci, primate, evolution and allelic diversity of, 30:110
MHC class II molecules, negative signal transmission through on activated T cells, 31:170
MHC class II molecules, signal transduction, 30:202
MHC class II typing, serologic analysis of phytohemagglutinin and interleukin-2 stimulated peripheral blood mononuclear cells, 30:222
MHC DRB alleles, primate, phylogeny of, an hypothesis, 31:28
MHC nonclassical class I genes, a physical linkage map of HLA-A, -G, -7.5, and -F, 31:180
MhcMamu-DR subregion, RFLP analysis, 30:11
Micronesians, HLA-DR4-related HLA-DR,DQ haplotypes, 32:269
Minor lymphocyte stimulating (*Mls*) locus gene products, presentation by HLA-DQβ chains and deletion of Vβ6$^+$, Vβ8.1$^+$ T cells, 31:47
Mixed lymphocyte culture (MLC), oligonucleotide typing to identify stimulatory antigens, 31:241
Monoclonal antibodies, human,
  epitope mapping of natural and mutated variants of HLA-B27, 31:271
  HLA-DRw11 and HLA-DRw8+w12 specific, 31:86
Monoclonal antibody, broad anti-HLA-DR activity, 30:174
Mucocutaneous leishmaniasis, *See* Leishmaniasis, mucocutaneous
Mulatto population, allergic asthma and HLA-DPB1*0401, 32:157
Multidrug resistance gene (*mdr1*), product activity in lymphocytes, 32:134
Multiple sclerosis,
  HLA-DQA1 and -DQB1 genes and susceptibility, 30:69
  HLA-DR and -DQ allelic sequences in, 32:203
  Northern Irish patients, HLA-DR and DQ DNA genotyping, 30:1
  susceptibility and HLA-DR or -DQ, 32:119
  viral antibody titers and HLA class II markers in patients and controls, 31:94

Neutrophil-specific NA1 antigen, autoimmunization to associated with HLA-DR2, 30:18
Nomenclature report, WHO committee, factors of the HLA system, 1990, 31:186
Nonclassical HLA class I gene characterization of expression, 32:102
Noninherited maternal HLA antigens (NIMA), anti-idiotypic antibodies to HLA class I alloantibodies, 31:1
Non-MHC genes, contribution to autoimmune diseases, 32:1
Non-MHC-restricted cytotoxicity, control by x-linked codominant genes, 30:208
Northern Irish, multiple sclerosis patients, HLA-DR and DQ DNA genotyping, 30:1

OKT4, *See* CD4

Parasites, coevolution of MHC and, 30:247
Pemphigus vulgaris, Japanese patients, HLA class II antigens and, 31:246
Peptide transporters, *mdr1* product activity in lymphocytes, 32:134
Phytohemagglutinin and interleukin-2, peripheral blood mononuclear cell response and serologic typing for MHC class II antigens, 30:222
Polynesians, HLA-DR4-related HLA-DR,DQ haplotypes, 32:269
Primate MHC class II loci, *See* MHC class II loci, primate
Primate MHC Workshop, Oegstgeest, The Netherlands, 1989,

evolution of allelic diversity at the primate MHC class II loci, 30:110
evolution of class I MHC genes in humans and apes, 30:119
MHC ancestral haplotypes in the chimpanzee, C4 allotyping, 31:34
phylogeny of primate MHC DRB alleles, 31:28
signal transduction in B lymphocytes, 30:202

Recurrent spontaneous abortion, *See* Abortion, recurrent spontaneous
Rhesus monkey, MHC class II DR subregion, RFLP analysis of, 30:11
Rheumatoid arthritis, *See* Arthritis, rheumatoid

Sequence-specific oligonucleotide probes, HLA-DPB1 typing, 30:22
Serum lipid, inhibition of IFN-γ induction of HLA class II, 31:57
Signal transduction,
B lymphocytes, 30:202
HLA-DR, regulation by CD45 in activated T cells, 32:85
negative, through MHC class II molecules on activated T cells, 31:170
South African families of Black, Asian, Indian, and mixed ancestral origin, unusual HLA-DR,DQ haplotypes, 31:14
Spaniards, IDDM and frequency of HLA-DRB1*0405-(Dw15)-DQw8 haplotype, 32:170
Synovial lining cells, autocrine stimulation of IL-1, 31:261
Systemic lupus erythematosus, a rare HLA-DQB allele in, 30:77

T cell, antigen-specific recognition, contribution of TCR contracting and peptide binding residues of HLA-DR4 Dw10 to, 32:110
T-cell adhesion, down regulation by CD4, an hypothesis, 31:40
T-cell allorecognition of HLA-DR3 microvariants, HLA-DRw17 and HLA-DRw18, 32:46
T-cell clones,
alloreactive, identification of HLA-DQw3 variants, 30:32
identification of epitopes associated with HLA- Dw14, 32:229
TCR γ/δ⁺, preferential stimulation with anti-CD6 monoclonal antibodies, 31:165
T-cell receptor (TCR),
Vα gene polymorphism, 32:277
Vβ genes, differential expression in CD4 and CD8 T cells, 32:194
T-cell receptor (TCR) β-chain genes, germline repertoire in IDDM patients, 31:77
T-cell recognition of HLA-DR alloantigens, 30:215
T-cell response, in highly sensitized patients to HLA class I alloantigens, 30:156
T-cell response to cancer, 30:259
T cells,
CD4⁺ and CD8⁺, differential expression of TCR Vβ genes, 32:194
cytotoxic, loss of reactivity in lymphoid cells infiltrating heart transplants, 30:50
deletion of Vβ6⁺, Vβ8.1⁺ by HLA-DQβ chain presenting *Mls* locus gene products, 31:47
germinal center, a distinct subset, 31:67
helper-inducer and a distinct subset of germinal center T cells, 31:67
recognition of allospecificities associated with HLA-Bw4/Bw6 public epitopes, 32:41
role in autoimmunity in non-human primates, 32:31
T cells, activated,
CD45 regulation of HLA-DR signal transduction, 32:85
enhanced expression of HLA class II with TNF-α treatment, 31:286
negative signal transmission through MHC class II molecules, 31:170
Transfection, HLA genomic DNA, 31:293
Transgenic mice, deletion of Vβ6⁺, Vβ8.1⁺ T cells by HLA-DQβ chain presenting *Mls* locus gene products, 31:47
Transplantation, discordant xenografting, 30:262
Transplantation, umbilical cord blood, DNA amplification for DQ typing for potential donors for, 30:45
Trophoblast-leukocyte common (TLX) antigen and CD46, 30:162
Tumor necrosis factor-α (TNF-α), enhanced expression of HLA class II on activated T cells, 31:286
Tyrosine kinase, HLA-DR mediated signal transduction in activated T cells, 32:85

Vα gene polymorphism, T-cell receptor, 32:277
Vβ genes, differential expression on CD4 and CD8 T cells, 32:194
Viral antibody titers, in multiple sclerosis patients, interrelations with HLA class II markers, 31:94

West African population, HLA-Bw53 origin in, 30:105

X-linked codominant genes, control of non-MHC-restricted cytotoxicity, 30:208
Xenografting, revisiting a challenge in transplantation, 30:262